843 related articles for article (PubMed ID: 30070323)
21. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
22. Maimendong and Qianjinweijing Tang combined with cisplatin suppressed lung cancer through targeting lncRNA-p21.
Xie M; Wang C; Sun Y; Mao Q; Sun S; Wu M; Zhu J; Li W; Jiang Z
J Ethnopharmacol; 2024 Mar; 322():117547. PubMed ID: 38135231
[TBL] [Abstract][Full Text] [Related]
23. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
24. LncRNA ASB16-AS1 promotes proliferation and inhibits apoptosis of non small cell lung cancer cells by activating the Wnt/β catenin signaling pathway.
Tan LJ; Liu JT; Yang M; Ju T; Zhang YS
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1870-1876. PubMed ID: 32141556
[TBL] [Abstract][Full Text] [Related]
25. Long Non-Coding RNA NNT-AS1 Contributes to Cisplatin Resistance via miR-1236-3p/ATG7 Axis in Lung Cancer Cells.
Wang H; Guo M; Ding D; Yang F; Chen Z
Onco Targets Ther; 2020; 13():3641-3652. PubMed ID: 32431515
[TBL] [Abstract][Full Text] [Related]
26. Silence of lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
Liu X; Huang Z; Qian W; Zhang Q; Sun J
J Cell Biochem; 2019 Jun; 120(6):9243-9249. PubMed ID: 30652341
[TBL] [Abstract][Full Text] [Related]
27. Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.
Shen Q; Zhou H; Zhang M; Wu R; Wang L; Wang Y; Chen J
J Clin Lab Anal; 2022 Jun; 36(6):e24460. PubMed ID: 35500152
[TBL] [Abstract][Full Text] [Related]
28. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
[TBL] [Abstract][Full Text] [Related]
29. LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis.
Liu Y; Guo R; Qiao Y; Han L; Liu M
Cancer Cell Int; 2020; 20():190. PubMed ID: 32489326
[TBL] [Abstract][Full Text] [Related]
30. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
31. LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells.
Tan D; Li G; Zhang P; Peng C; He B
Bioengineered; 2022 Jan; 13(1):1838-1857. PubMed ID: 35014944
[TBL] [Abstract][Full Text] [Related]
32. Long non-coding RNA SNHG15 indicates poor prognosis of non-small cell lung cancer and promotes cell proliferation and invasion.
Dong YZ; Meng XM; Li GS
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2671-2679. PubMed ID: 29771418
[TBL] [Abstract][Full Text] [Related]
33. Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer.
Li P; Li J; Yang R; Zhang F; Wang H; Chu H; Lu Y; Dun S; Wang Y; Zang W; Du Y; Chen X; Zhao G; Zhang G
Diagn Pathol; 2015 Jun; 10():63. PubMed ID: 26055877
[TBL] [Abstract][Full Text] [Related]
34. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation.
Fang Z; Chen W; Yuan Z; Liu X; Jiang H
Biomed Pharmacother; 2018 May; 101():536-542. PubMed ID: 29505924
[TBL] [Abstract][Full Text] [Related]
35. LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP.
Tan D; Wang S; Zhang P; Peng C; Wu T
Ann Clin Lab Sci; 2023 Jan; 53(1):64-75. PubMed ID: 36889771
[TBL] [Abstract][Full Text] [Related]
36. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
Wang W; Dong ML; Zhang W; Liu T
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
[TBL] [Abstract][Full Text] [Related]
37. LncRNA NNT-AS1 regulates the progression of lung cancer through the NNT-AS1/miR-3666/E2F2 axis.
Huang JW; Luo XY; Li ZH; Lang BP
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):238-248. PubMed ID: 31957837
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
39. Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells.
Lei X; Huang Z; Zhong M; Zhu B; Tang S; Liao D
Acta Biochim Biophys Sin (Shanghai); 2007 May; 39(5):344-50. PubMed ID: 17492131
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
Xia Y; He Z; Liu B; Wang P; Chen Y
Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
